Nuvation Bio has backed off from its plans to directly compare its brain cancer drug to Servier’s Voranigo, instead opting to focus on patients who aren’t covered by the approved…
Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune assets from U.S. biotech Kaigene. One of the antibodies, dubbed KG006, is…
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics…
Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder (AUD) candidate while the biotech considers its options, according to the program’s partner. The mGluR5 negative allosteric…
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game changer. The FDA no…
Roche may have been exploring ways to shuttle drugs to the brain for well over a decade, but that’s not stopping the pharma from handing $55 million to Manifold Bio…
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.…
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target. San Diego-based Neurocrine secured…
Pfizer has lived up to its threat of taking legal action to prevent Metsera from slipping out of its grasp, but the obesity biotech also seems up for the fight.…
Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody. In return…